Corrigendum: A novel treatment of cystic fibrosis acting on-Target: Cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR (Cell Death and Differentiation (2016) 23 DOI: 10.1038/cdd.2016.22);A novel treatment of cystic fibrosis acting on-target: Cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR

Cell Death and Differentiation

Volumn 23, Issue 8, 2016, Pages 1380-1393

  Tosco, A ^a   De Gregorio, F ^a   Esposito, S ^b   De Stefano, D ^b   Sana, I ^b   Ferrari, E ^b   Sepe, A ^a   Salvadori, L ^a   Buonpensiero, P ^a   Di Pasqua, A ^a   Grassia, R ^c   Leone, C A ^c   Guido, S ^a   De Rosa, G ^a   Lusa, S ^d   Bona, G ^e   Stoll, G ^f,g,h,i   Maiuri, M C ^g   Mehta, A ^j   Kroemer, G ^b,f,g,k,l,m   Maiuri, L ^b,e   Raia, V ^a,b   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h INSERM   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPIGALLOCATECHIN GALLATE; INTERLEUKIN 8; MERCAPTAMINE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CATECHIN; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOPHAGY; CFTR GENE; CYSTIC FIBROSIS; DRUG EFFICACY; GENE; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NOSE MUCOSA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY FUNCTION; SPUTUM; SWEAT; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; ANIMAL; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HOMOZYGOTE; KNOCKOUT MOUSE; LUNG; METABOLISM; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ANIMALS; AUTOPHAGY; BIOMARKERS; CATECHIN; CHILD; CYSTEAMINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HOMOZYGOTE; HUMANS; INTERLEUKIN-8; LUNG; MICE; MICE, KNOCKOUT; MUTATION; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84962121102     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2016.43     Document Type: Erratum

References (47)

1. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003; 361: 681-689
2. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014; 13: 403-409
3. Ramsey BW, Davies J, McElvaney NG, Bell SC, Drevinek P, Griese M, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672
4. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. TRAFFIC and TRANSPORT Study GroupsLumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015; 373: 220-231
5. Boyle A MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. VX09-809-102 study group. CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014; 2: 527-538
6. Davis PB. Another beginning for cystic fibrosis therapy. N Engl J Med 2015; 373: 274-276
7. Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax 2015; 70: 615-616
8. Amaral MD, Farinha CM. Rescuing mutant CFTR: a multi-Task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 2013; 19: 3497-3508
9. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, et al. Potentiator ivacaftor abrogates pharmacological correction of ?F508 CFTR in cystic fibrosis. Sci Transl Med 2014; 6: 246ra96
10. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, et al. Some gating potentiators, including VX-770, diminish ?F508-CFTR functional expression. Sci Transl Med 2014; 6: 246ra97
11. Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 2014; 13: 139-147
12. De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, et al. European Cystic Fibrosis Society Clinical Trial Network Standardisation CommitteeCFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013; 41: 203-216
13. Amaral MD. Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. Intern Med 2015; 277: 155-166
14. Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Sole A, et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2014; 2: 147-153
15. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803-815
16. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12: 863-875
17. Venerando A, Franchin C, Cant N, Cozza G, Pagano MA, Tosoni K, et al. Detection of phospho-sites generated by protein kinase CK2 in CFTR: mechanistic aspects of Thr1471 phosphorylation. PloS One 2013; 8: e74232
18. GahlWA. Early oral cysteamine therapy for nephropathic cystinosis. Eur J Pediatr 2003; 162: S38-S41
19. Emma F, Nesterova G, Langman C, Labbè A, Cherqui S, Goodyer P, et al. Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant 2014; 29: 87-94
20. De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, et al. Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy 2014; 10: 2053-2074
21. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DF508 cystic fibrosis transmembrane conductance regulator. Autophagy 2012; 8: 1657-1672
22. Villella VR, Esposito S, Bruscia EM, Vicinanza M, Cenci S, Guido S, et al. Disease-relevant proteostasis regulation of cystic fibrosis transmembrane conductance regulator. Cell Death Differ 2013; 20: 1101-1115
23. Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax 2012; 67: 860-866
24. DeMarco ML, Dietzen DJ, Brown SM. Sweating the small stuff: Adequacy and accuracy in sweat chloride determination. Clin Biochem 2014; 48: 443-447
25. Corvol H, Thompson KE, Tabary O, le Rouzic P, Guillot L. Translating the genetics of cystic fibrosis to personalized medicine. Transl Res 2015; 168: 40-49
26. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 1036-1043
27. Schork NJ. Personalized medicine: time for one-person trials. Nature 2015; 520: 609-611
28. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-2234
29. Bilton D. Personalised medicine in cystic fibrosis must be made affordable. Paediatr Respir Rev 2014; 155: 6-7
30. Bosch B, De Boeck K. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr 2015; 175: 1-8
31. Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015; 14: 419-430
32. vanDoorninck JH, French PJ, Verbeek E, Peters RH, Morreau H, Bijman J, et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995; 14: 4403-4411
33. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992; 257: 1083-1088
34. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112: 1809-1820
35. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, Matthay MA. Partial restoration of defective chloride conductance in DF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 2001; 281: L52-L57
36. Illek B, Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 1998; 275: L902-L910
37. Marchelletta RR, Gareau MG, McCole DF, Okamoto S, Roel E, Klinkenberg R, et al. Altered expression and localization of ion transporters contribute to diarrhea in mice with Salmonellainduced enteritis. Gastroenterol 2013; 145: 1358-1368
38. Gondzik V, Awayda MS. Methods for stable recording of short-circuit current in a Na+-Transporting epithelium. Am J Physiol Cell Physiol 2011; 301: C162-C170
39. Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D?Apolito M, et al. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPAR gamma down-regulation. J Immunol 2008; 180: 7697-7705
40. Amano H, Yamamoto H, Senba M, Oishi k, Suzuki S, Fukushima K, et al. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin-induced diabetes in mice. Infect Immun 2000; 68: 2925-2929
41. Stern M, Munkonge FM, Caplen NJ, Sorgi F, Huang L, Geddes DM, et al. Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther 1995; 2: 766-774
42. Verkman AS, Galietta LJV. Chloride channels as drug targets. Nat Rev Drug Discov 2009; 8: 153-171
43. Jayaraman S, Teitler L, Skalski B, Verkman A. Longwavelength iodide-sensitive fluorescent indicators for measurement of functional CFTR expression in cells. Am J Physiol Cell Physiol 1999; 277: C1008-C1018
44. Munkonge F, Alton EW, Andersson C, Davidson H, Dragomir A, Edelman A, et al. Measurement of halide efflux from cultured and primary airway epithelial cells using fluorescence indicators. J Cyst Fibros 2004; 3: 171-176
45. Mansoura MK, Biwersi J, Ashlock MA, Verkman A. Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery. Hum Gene Ther 1999; 10: 861-875
46. Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40: 90-97
47. Abdi H. Bonferroni and Sidak corrections for multiple comparison. In: Salkind NJ (eds). Encyclopedia of Measurement and Statistics. Sage: Thousand Oaks, CA, USA, 2007, pp 103-107